-
2 months ago | 
medscape.com | Robert Harrington |C. Michael Gibson
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts Manage Email Alerts
-
Jan 8, 2025 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoJanuary 8, 2025Author(s):, Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic. It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment. This condition affects a smaller subset of patients with high blood pressure and requires a comprehensive management approach.
-
Jan 8, 2025 | 
consultantlive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
Advancing Hypertension Management: Unmet Needs, Endothelial Dysfunction, and CKD Therapies - Episode 11Published on: , , , Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control. Patient No. 2 has stage 3 CKD and uncontrolled hypertension.
-
Dec 11, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 11, 2024Author(s):, Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic. It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment. This condition affects a smaller subset of patients with high blood pressure and requires a comprehensive management approach.
-
Dec 11, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 11, 2024Author(s):, Antihypertensive drug classes include diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, and alpha-blockers, each with distinct mechanisms of action targeting blood pressure regulation. Diuretics reduce blood volume, beta-blockers decrease heart rate, ACE inhibitors and ARBs inhibit the renin-angiotensin-aldosterone system, and calcium channel blockers relax blood vessels.
-
Dec 10, 2024 | 
medscape.com | Robert Harrington |Manesh R. Patel |C. Michael Gibson
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts
-
Dec 4, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 4, 2024Author(s):, Traditional antihypertensive drugs often result in variable patient responses and side effects, complicating treatment efficacy and patient adherence. Lifelong administration of these medications can lead to compliance issues, impacting long-term management of hypertension. Current treatments primarily manage symptoms rather than addressing the underlying pathophysiology of hypertension.
-
Dec 4, 2024 | 
consultantlive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
Advancing Hypertension Management: Unmet Needs, Endothelial Dysfunction, and CKD Therapies - Episode 2Current Limitations With Traditional Antihypertensive DrugsPublished on: December 4, 2024Manesh R. Patel, MD, Payal Kohli, MD, FACC, John M. Flack, MD, MPH, FASH, C.
-
Dec 4, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 4, 2024Author(s):, Patient adherence to antihypertensive regimens is crucial for effective blood pressure control, with non-adherence leading to suboptimal outcomes and increased health risks. Comorbid conditions like CKD complicate hypertension management, requiring tailored therapeutic approaches and careful monitoring to achieve optimal blood pressure control.
-
Oct 14, 2024 | 
nature.com | Faiez Zannad |C. Michael Gibson |Cecilia Linde |Thomas F. Luscher |Thomas F. Lüscher |Richard Mindham | +3 more
AbstractCardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination.
